ATE426405T1 - Amino-substituierte diarylaa,ducyclohepten- analoga als muscarinische agonisten und verfahren zur behandlung von neuropsychiatrischen erkrankungen - Google Patents

Amino-substituierte diarylaa,ducyclohepten- analoga als muscarinische agonisten und verfahren zur behandlung von neuropsychiatrischen erkrankungen

Info

Publication number
ATE426405T1
ATE426405T1 AT04815318T AT04815318T ATE426405T1 AT E426405 T1 ATE426405 T1 AT E426405T1 AT 04815318 T AT04815318 T AT 04815318T AT 04815318 T AT04815318 T AT 04815318T AT E426405 T1 ATE426405 T1 AT E426405T1
Authority
AT
Austria
Prior art keywords
amino
ducycloheptene
diarylaa
analogas
substituted
Prior art date
Application number
AT04815318T
Other languages
German (de)
English (en)
Inventor
Fredrik Ek
Roger Olsson
Jirgen Ohlsson
Original Assignee
Acadia Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acadia Pharm Inc filed Critical Acadia Pharm Inc
Application granted granted Critical
Publication of ATE426405T1 publication Critical patent/ATE426405T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/38—[b, e]- or [b, f]-condensed with six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
AT04815318T 2003-12-22 2004-12-21 Amino-substituierte diarylaa,ducyclohepten- analoga als muscarinische agonisten und verfahren zur behandlung von neuropsychiatrischen erkrankungen ATE426405T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53192703P 2003-12-22 2003-12-22
US54809004P 2004-02-24 2004-02-24
US54860404P 2004-02-27 2004-02-27

Publications (1)

Publication Number Publication Date
ATE426405T1 true ATE426405T1 (de) 2009-04-15

Family

ID=34743692

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04815318T ATE426405T1 (de) 2003-12-22 2004-12-21 Amino-substituierte diarylaa,ducyclohepten- analoga als muscarinische agonisten und verfahren zur behandlung von neuropsychiatrischen erkrankungen

Country Status (22)

Country Link
US (5) US7550454B2 (enExample)
EP (2) EP1696931B1 (enExample)
JP (1) JP2007534656A (enExample)
KR (1) KR101157881B1 (enExample)
CN (1) CN101962369A (enExample)
AT (1) ATE426405T1 (enExample)
AU (1) AU2004308955B2 (enExample)
BR (1) BRPI0417749A (enExample)
CA (1) CA2550735A1 (enExample)
CY (1) CY1109171T1 (enExample)
DE (1) DE602004020263D1 (enExample)
DK (1) DK1696931T3 (enExample)
ES (1) ES2324713T3 (enExample)
IL (1) IL176447A0 (enExample)
MX (1) MXPA06007244A (enExample)
NO (1) NO20063371L (enExample)
NZ (1) NZ547911A (enExample)
PL (1) PL1696931T3 (enExample)
PT (1) PT1696931E (enExample)
SG (1) SG133606A1 (enExample)
SI (1) SI1696931T1 (enExample)
WO (1) WO2005063254A2 (enExample)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100879647B1 (ko) 2000-03-06 2009-01-20 아카디아 파마슈티칼스 인코포레이티드 세로토닌 관련 질병의 치료에 사용되는 아자시클릭 화합물
NZ533567A (en) 2001-12-28 2007-06-29 Acadia Pharm Inc Spiroazacyclic compounds as monoamine receptor for modulating 5-HT2A receptor-mediated events
JP4414237B2 (ja) * 2002-03-20 2010-02-10 テバ ファーマシューティカル インダストリーズ リミティド ケチアピンヘミフマレートの結晶形
US7538222B2 (en) 2002-06-24 2009-05-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
US7253186B2 (en) 2002-06-24 2007-08-07 Carl-Magnus Andersson N-substituted piperidine derivatives as serotonin receptor agents
JP2005533813A (ja) 2002-06-24 2005-11-10 アカディア ファーマシューティカルズ，インコーポレーテッド セロトニン受容体作用物質としてのｎ−置換ピペリジン誘導体
ATE407117T1 (de) 2003-01-16 2008-09-15 Acadia Pharm Inc Selektive serotonin 2a/2c inverse rezeptoragonisten als therapeutika für neurodegenerative erkrankungen
WO2004064753A2 (en) * 2003-01-23 2004-08-05 Acadia Pharmaceuticals Inc Use of n-desmethylclozapine to treat human neuropsychiatric disease
US20050250767A1 (en) * 2003-01-23 2005-11-10 Weiner David M Use of N-desmethylclozapine to treat human neuropsychiatric disease
US20050085463A1 (en) * 2003-01-23 2005-04-21 Weiner David M. Use of N-desmethylclozapine to treat human neuropsychiatric disease
NZ527142A (en) 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
WO2008021463A2 (en) * 2006-08-15 2008-02-21 Acadia Pharmaceuticals, Inc. Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
US20090239840A1 (en) * 2003-12-22 2009-09-24 Acadia Pharmaceuticals, Inc. AMINO SUBSTITUTED DIARYL[a,d]CYCLOHEPTENE ANALOGS AS MUSCARINIC AGONISTS AND METHODS OF TREATMENT OF NEUROPSYCHIATRIC DISORDERS
BRPI0417749A (pt) 2003-12-22 2007-04-10 Acadia Pharm Inc composto, método de sintese de composto, bibliotecas combinatórias, composições farmacêuticas e métodos de tratamento de disfunções neuropsiquiátricas
US20050171088A1 (en) * 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic
BRPI0509524A (pt) * 2004-04-01 2007-09-18 Acadia Pharm Inc formas cristalinas de n-desmetilclozapina
US7820695B2 (en) 2004-05-21 2010-10-26 Acadia Pharmaceuticals, Inc. Selective serotonin receptor inverse agonists as therapeutics for disease
US20050261278A1 (en) * 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
US7879834B2 (en) 2004-08-19 2011-02-01 Vertex Pharmaceuticals Incorporated Spiroindoline modulators of muscarinic receptors
US7786141B2 (en) 2004-08-19 2010-08-31 Vertex Pharmaceuticals Incorporated Dihydrospiroindene modulators of muscarinic receptors
US20060081361A1 (en) * 2004-09-13 2006-04-20 Gabbey Lawrence W Oil cooler with integral filter
US7790899B2 (en) 2004-09-27 2010-09-07 Acadia Pharmaceuticals, Inc. Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
CN101031548B (zh) * 2004-09-27 2011-04-06 阿卡蒂亚药品公司 N-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n'-(4-(2-甲基丙氧基)-苯基甲基)脲的盐及其制备
JP2008521825A (ja) * 2004-11-29 2008-06-26 バーテックス ファーマシューティカルズ インコーポレイテッド ムスカリン受容体のモジュレーター
EP1838325A1 (en) * 2005-01-07 2007-10-03 AstraZeneca AB NEW USE OF 11-PIPERAZIN-1-YLDIBENZO [b,f][1,4]THIAZEPINE OR ITS PHARMACEUTICALLY ACCEPTABLE SALT AND TO ORAL PHARMACEUTICAL COMPOSITIONS
US20060252744A1 (en) * 2005-04-04 2006-11-09 Burstein Ethan S Use of N-desmethylclozapine and related compounds as dopamine stabilizing agents
JP2008502707A (ja) * 2005-04-14 2008-01-31 テバ ファーマシューティカル インダストリーズ リミティド クエチアピンフマレートの調製方法
EP2275096A3 (en) 2005-08-26 2011-07-13 Braincells, Inc. Neurogenesis via modulation of the muscarinic receptors
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP1937677A1 (en) * 2005-10-17 2008-07-02 Arcadia Pharmaceuticals Inc. Cb-1 modulating compounds and their use
US20070106074A1 (en) * 2005-10-17 2007-05-10 Roger Olsson Iron catalyzed cross-coupling reactions of imidoyl derivatives
US20080090805A1 (en) * 2005-10-17 2008-04-17 Acadia Pharmaceuticals Inc. Cb-1 modulating compounds and their use
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
WO2007053618A1 (en) * 2005-10-31 2007-05-10 Acadia Pharmaceuticals Inc. Prodrugs of muscarinic agonists and methods of treatment of neuropsychiatric disorders
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20070105835A1 (en) * 2005-11-07 2007-05-10 Kazantsev Aleksey G Compositions and methods for modulating poly(ADP-ribose) polymerase activity
EP1951694A4 (en) * 2005-11-18 2010-09-22 Astrazeneca Ab FORMS OF SALTS
WO2008079847A1 (en) * 2006-12-20 2008-07-03 Astrazeneca Ab (Se/Se) Compounds and uses thereof
JP2009516708A (ja) * 2005-11-18 2009-04-23 アストラゼネカ・アクチエボラーグ 液体製剤
US8003660B2 (en) 2006-02-22 2011-08-23 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
CA2652300A1 (en) * 2006-05-15 2007-11-22 Acadia Pharmaceuticals Inc. Pharmaceutical formulations of pimavanserin
DE102006032427A1 (de) * 2006-07-13 2008-01-17 Neuraxpharm Arzneimittel Gmbh U. Co. Kg Verwendung von Zusammensetzungen von Clozapin, Quetiapin, schwer oder sehr schwer löslichen Säureadditionssalzen von Quetiapin und/oder Olanzapin zur Herstellung von Lösungen zur oralen Verabreichung
DE102006032426A1 (de) * 2006-07-13 2008-01-17 Neuraxpharm Arzneimittel Gmbh U. Co. Kg Verwendung von Zusammensetzungen von Clozapin, Quetiapin, schwer oder sehr schwer löslichen Säureadditionssalzen von Quetiapin und/oder Olanzapin zur Herstellung von Lösungen zur oralen Verabreichung
US7786107B2 (en) * 2006-08-18 2010-08-31 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
WO2008030651A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008118141A2 (en) * 2006-10-17 2008-10-02 Acadia Pharmaceuticals Inc. Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy
JP2010514684A (ja) * 2006-12-20 2010-05-06 アストラゼネカ・アクチエボラーグ 化合物及びその使用
GB0701970D0 (en) * 2007-02-01 2007-03-14 Wilson Stuart Treatment of protein aggregation diseases
DK2137180T3 (da) * 2007-03-15 2012-07-02 Andaman Therapeutics Inc Dibenzo[B,F][1,4]oxazapinforbindelser
WO2008116024A2 (en) 2007-03-19 2008-09-25 Acadia Pharmaceuticals Inc. Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics
JP2010540640A (ja) * 2007-10-03 2010-12-24 バーテックス ファーマシューティカルズ インコーポレイテッド ムスカリン作用性レセプターのモジュレーター
EP2303897A4 (en) 2008-06-05 2012-02-22 Harvard College HIGH VALENCIA PALLADIUM FLUORIDE COMPLEXES AND USES THEREOF
CA2728675A1 (en) 2008-06-20 2009-12-23 Astrazeneca Ab Dibenzothiazepine derivatives and use thereof
WO2010062565A1 (en) * 2008-10-27 2010-06-03 Acadia Pharmaceuticals Inc. Muscarinic agonists
WO2010059943A2 (en) 2008-11-20 2010-05-27 President And Fellows Of Harvard College Fluorination of organic compounds
EP2385944A4 (en) * 2009-01-09 2013-06-19 Harvard College FLUORINARY COMPOUNDS AND METHOD OF USE THEREOF
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CN101531570B (zh) * 2009-04-17 2012-10-10 中国科学院上海有机化学研究所 1，2-取代-5-乙炔基-(或10，11-二氢)-5H-二苯基[a，d]环庚烯(烷)-5-醇、合成方法及用途
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
ES2742728T3 (es) 2009-07-22 2020-02-17 PureTech Health LLC Composiciones para el tratamiento de trastornos mejorados por la activación del receptor muscarínico
WO2011025748A1 (en) * 2009-08-26 2011-03-03 Acadia Pharmaceuticals, Inc. Amino substituted diaryl [a, d] cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
CN103596931B (zh) 2011-04-12 2016-10-12 哈佛大学校长及研究员协会 有机化合物的氟化
US9273083B2 (en) 2012-09-26 2016-03-01 President And Fellows Of Harvard College Nickel fluorinating complexes and uses thereof
US11465978B2 (en) 2013-09-11 2022-10-11 The Administrators Of The Tulane Educational Fund Anthranilic amides and the use thereof
WO2015058047A2 (en) 2013-10-18 2015-04-23 President And Fellows Of Harvard College Fluorination of organic compounds
CN104016937B (zh) * 2014-05-09 2016-12-07 中科院广州化学有限公司 一种n-芳基氧氮杂卓酮类化合物及其制备方法
CN111909173B (zh) * 2015-07-02 2025-03-04 豪夫迈·罗氏有限公司 苯并氧氮杂䓬噁唑烷酮化合物及其使用方法
CN107848972B (zh) 2015-07-20 2021-06-18 阿卡蒂亚药品公司 用于制备n-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n’-(4-(2-甲基丙氧基)苯基甲基)脲及其酒石酸盐和多晶型c的方法
WO2017165635A1 (en) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome p450 modulators
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
EP3558311A1 (en) 2016-12-20 2019-10-30 Acadia Pharmaceuticals Inc. Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis
TW201831462A (zh) * 2017-01-25 2018-09-01 日商大日本住友製藥股份有限公司 二苯并二氮呯衍生物
WO2018148529A1 (en) * 2017-02-10 2018-08-16 Florida A&M University Identification of agents displaying functional activation of dopamine d2 and d4 receptors
WO2018200977A1 (en) 2017-04-28 2018-11-01 Acadia Pharmaceuticals Inc. Pimavanserin for treating impulse control disorder
WO2019046167A1 (en) 2017-08-30 2019-03-07 Acadia Pharmaceuticals Inc. PIMAVANSERIN FORMULATIONS
US11518755B2 (en) 2017-10-06 2022-12-06 Leyden Technologies B.V. Stable solutions of multicyclic antidepressants
CN107903244B (zh) * 2017-11-29 2019-06-14 武汉珈创生物技术股份有限公司 具有抗肿瘤活性的2-胺基取代苯并二氮卓化合物及其制备方法
CN111670050A (zh) 2018-01-30 2020-09-15 爱普宁公司(特拉华) 用于治疗睡眠呼吸暂停的方法和组合物
JP2021104931A (ja) * 2018-02-22 2021-07-26 大日本住友製薬株式会社 含窒素複素環を有するジベンゾアゼピン誘導体
CN110627735A (zh) * 2018-06-25 2019-12-31 江阴安博生物医药有限公司 一种新的喹硫平类似物及其制备方法和应用
PT3856182T (pt) 2018-09-28 2026-03-10 Karuna Therapeutics Inc Composições e métodos para o tratamento de perturbações melhoradas pela ativação dos recetores muscarínicos
CN114929688B (zh) 2019-10-21 2024-11-01 阿莱瑞恩公司 作为H1和5-HT2A-受体调节剂、用于治疗睡眠障碍的3-(4-(11H-二苯并[b,e][1,4]吖庚英-6-基)哌嗪-1-基)-和3-(4-(二苯并[b,f][1,4]氧杂吖庚英/硫杂吖庚英/二吖庚英-11-基)哌嗪-1-基)-丙酸衍生物
CN112358455B (zh) * 2020-11-16 2022-07-19 吉林奥来德光电材料股份有限公司 一种二苯并七元杂环类化合物及其制备方法与应用
TWI820605B (zh) * 2022-02-18 2023-11-01 國立臺灣大學 抗菌化合物、其製備方法及其用途

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR870763A (fr) 1939-12-19 1942-03-24 Zeiss Ikon Ag Procédé destiné à faire disparaître les bruits produits par les boucles du film dans les appareils de prise de vues et de reproduction, en particulier pour la priseet la reproduction de films sonores
CH240228A (de) 1944-07-28 1945-12-15 Ciba Geigy Schaumisoliermasse auf Kunstharzbasis.
FR939591A (fr) 1946-01-09 1948-11-18 Philips Nv Récepteur de télévision
FR939595A (fr) 1947-01-08 1948-11-18 Perfectionnements apportés aux tuiles à recouvrement en matériaux de toute nature
FR51M (enExample) 1960-06-03 1960-11-28
CH422793A (de) 1961-07-20 1966-10-31 Wander Ag Dr A Verfahren zur Herstellung 11-basisch substituierter Dibenzo(b,f) (1,4)thiazepine
FR1334944A (fr) 1961-08-11 1963-08-16 Wander Ag Dr A Procédé de préparation d'amidines de la série des 5-dibenzo-[b,e] [1,4]-diazépines
CH476753A (de) 1962-06-08 1969-08-15 Wander Ag Dr A Verfahren zur Herstellung von 11-basisch substituierter Dibenzo(b,f)(1,4)thiazepine
DE1620712A1 (de) * 1962-05-25 1970-06-04 Wander Ag Dr A Verfahren zur Herstellung 11-basisch substituierter Dibenzo-[b,f][1,4]-thiazepine
NL140242B (nl) * 1963-03-01 1973-11-15 Wander Ag Dr A Werkwijze voor het bereiden van op de 11-plaats door een basische groep gesubstitueerde dibenz (b.f.)(1.4) oxazepinen.
US3389139A (en) * 1963-06-14 1968-06-18 Wander Ag Dr A 6-homopiperazino and piperazinomorphanthridines
GB1006156A (en) 1963-06-14 1965-09-29 Wander Ag Dr A 6-basic substituted morphanthridines
US3908010A (en) * 1967-03-22 1975-09-23 Wander Ag Dr A Basically substituted heterocycles as anti-emetics
US3884920A (en) * 1967-07-14 1975-05-20 Sandoz Ag 11-Basically substituted dibenz {8 b,f{9 {0 {8 1,4{9 {0 oxazepines
AT258912B (de) 1964-05-27 1967-12-27 Wander Ag Dr A Verfahren zur Herstellung neuer 11-basisch substituierter Dibenz [b,f] [1,4]oxazepine
US3412193A (en) * 1965-12-13 1968-11-19 American Cyanamid Co 11-(4-methyl-1-piperazinyl)dibenz[b, f][1, 4]oxazepines or thiazepines for controlling fertility
US3444169A (en) * 1966-01-17 1969-05-13 American Cyanamid Co Process for 11 - aminodibenz(b,f)(1,4)oxazepines and analogous thiazepines
GB1184251A (en) * 1966-04-15 1970-03-11 American Cyanamid Co Oxazepines and Thiazepines
GB1192812A (en) * 1966-05-20 1970-05-20 American Cyanamid Co 2-Chloro-11-(1-Piperazinyl)Dibenz[b,f]-[1,4]Oxazepine, Non-Toxic Acid Addition Salts thereof, and Therapeutic Compositions containing said Oxazepine or Salts
NL6715650A (enExample) 1966-12-16 1968-06-17
GB1177957A (en) 1966-12-23 1970-01-14 American Cyanamid Co Production of Oxazepines and Thiazepines
CA979441A (en) 1967-02-27 1975-12-09 American Cyanamid Company 11-(piperazinyl) dibenz (b,f) (1,4) oxazepines and analogous thiazepines
US3852446A (en) * 1967-03-13 1974-12-03 Sandoz Ag Organic compounds in treatment of psychotic disturbances
CH499539A (de) 1967-03-13 1970-11-30 Wander Ag Dr A Verfahren zur Herstellung 11-basisch substituierter Dibenz(b,f)-1,4-oxazepine, Dibenzo(b,f)-1,4-thiazepine und Dibenzo(b,e)-1,4,diazepine
DE1720007A1 (de) 1967-03-13 1971-05-19 Wander Ag Dr A Basisch substituierte Heterocyclen
US3758479A (en) * 1967-03-22 1973-09-11 Sandoz Ag Nitro and sulphamoyl substituted dibenzodiazepines
US3539573A (en) * 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
US3751415A (en) * 1967-03-22 1973-08-07 Sandoz Ag 2-nitro-11-(1-piperazinyl)-dibenz(b,f)(1,4)oxazepines
CA918659A (en) * 1969-07-31 1973-01-09 Yoshitomi Pharmaceutical Industries 11-(4-substituted-1-piperazinyl)-dibenzo (b,f) (1,4) thiazepines
NL7110453A (enExample) 1970-08-06 1972-02-08 Wander Ag Dr A
US3660406A (en) * 1970-10-26 1972-05-02 American Cyanamid Co 2-chloro-7-hydroxy-11-(1-piperazinyl)dibenz(b f)(1 4)oxazepines
CH555856A (de) * 1971-05-04 1974-11-15 Hoffmann La Roche Verfahren zur herstellung von tricyclischen verbindungen.
US3962248A (en) * 1972-04-04 1976-06-08 Sandoz, Inc. Process for making 11-piperazino-diazepines, oxazepines, thiazepines and azepines
CH569730A5 (enExample) 1972-04-04 1975-11-28 Wander Ag Dr A
CH585222A5 (en) 1973-02-14 1977-02-28 Wander Ag Dr A Prepn. of antipsychotic heterocyclic piperazine derivs. - by reaction of heterocyclic ketones with metal piperazine complexes
NL7403657A (enExample) 1973-03-23 1974-09-25
US3983234A (en) * 1974-07-04 1976-09-28 Sandoz Ltd. Treatment of dyskinesias
DE2625258A1 (de) 1975-06-06 1976-12-09 Hoffmann La Roche Dibenzo eckige klammer auf b,f eckige klammer zu thiepinderivat
SE7610219L (sv) 1975-09-24 1977-03-25 Sandoz Ag Nya dibenso /b,e//1,4/ diazepiner
US4045445A (en) * 1975-12-14 1977-08-30 American Cyanamid Company 11-(4-Piperidyl)dibenzo-diazepines
CS179793B1 (en) 1976-02-13 1977-11-30 Miroslav Protiva Biological derivative of 11-/4-methylpiperazino/-5h-dib)nzo/b,e/-1,4-diazepine
CH601288A5 (en) 1976-06-09 1978-07-14 Sandoz Ag 11-Piperazino-5H-di:benzodiazepine derivs.
US4406900A (en) * 1976-11-10 1983-09-27 Sandoz Ltd. Neuroleptic use of morphanthridines
CH624682A5 (enExample) * 1976-11-10 1981-08-14 Sandoz Ag
US4191760A (en) * 1977-02-23 1980-03-04 Abbott Laboratories Dibenzodiazepines
US4097597A (en) * 1977-02-23 1978-06-27 Abbott Laboratories Dibenzo b,e! 1,4!diazepines
US4096261A (en) * 1977-02-23 1978-06-20 Abbott Laboratories Dibenzodiazepines
DD133235A1 (de) 1977-10-10 1978-12-20 Carla Rueger Verfahren zur herstellung von in 11-stellung basisch substituierten 5h-dibenzo eckige klammer auf b,e eckige klammer zu eckige klammer auf 1,4 eckige klammer zu diazepinen
CS196893B1 (en) * 1977-12-22 1980-04-30 Miroslav Protiva 3-fluor-10-piperazino-8-substituted 10,11-dihydro-dibenzothiepines
US4263207A (en) * 1978-08-01 1981-04-21 Merck & Co., Inc. 10,11-Dihydrodibenzo[b,f][1,4]thiazepine carboxylic acids esters and amides thereof
US4404137A (en) * 1979-10-16 1983-09-13 Lilly Industries Limited Pyrazolo [3,4-b][1,5]benzodiazepine compounds
US4663453A (en) * 1983-05-18 1987-05-05 Hoechst-Roussel Pharmaceuticals Inc. Benzo[b]pyrrolo[3,2,1-jk][1,4]benzodiazepines having dopamine receptor activity
US4764616A (en) 1983-05-18 1988-08-16 Hoechst-Roussel Pharmaceuticals Inc. Benzopyrrolobenzodiazepines and quinobenzodiazepines
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
JPH04211071A (ja) * 1990-03-05 1992-08-03 Hokuriku Seiyaku Co Ltd 多環式化合物
BE1004596A4 (fr) 1990-09-26 1992-12-22 Therabel Res S A N V Derives de methylpiperazinoazepine, leur preparation et leur utilisation.
US5817655A (en) * 1991-04-23 1998-10-06 Eli Lilly And Company Methods of treatment using a thieno-benzodiazepine
US5300422A (en) * 1991-12-04 1994-04-05 Case Western Reserve University Screening method for controlling agranulocytosis
US5393752A (en) * 1992-05-26 1995-02-28 Therabel Research S.A./N.V. Methylpiperazinoazepine compounds, preparation and use thereof
US5962664A (en) * 1993-05-13 1999-10-05 Friedhoff; Arnold J. Psychosis protecting nucleic acid, peptides, compositions and method of use
US5354747A (en) * 1993-06-16 1994-10-11 G. D. Searle & Co. 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9- and/or 10-substituted dibenzoxazepine and dibenzthiazepine compounds, pharmaceutical compositions and methods of use
IL110298A (en) * 1993-07-13 1999-04-11 Brann Mark Robert Identification of ligands by selective amplification of cells transfected with receptors
US5538965A (en) 1993-12-23 1996-07-23 Allelix Biopharmaceuticals Inc. Dopamine receptor ligands
US6566065B1 (en) * 1994-05-26 2003-05-20 Mcgill University Method of diagnosing schizophrenia by detecting a mutation in the (MTHFR) gene
GB2292685A (en) 1994-07-27 1996-03-06 Sankyo Co Allosteric effectors at muscarinic receptors
US5700445A (en) * 1994-12-12 1997-12-23 Allelix Biopharmaceuticals, Inc. N-methyl piperazine compounds having dopamine receptor affinity
US5602124A (en) * 1994-12-12 1997-02-11 Allelix Biopharmaceuticals, Inc. 5-HT2 receptor ligands
US5602120A (en) 1994-12-12 1997-02-11 Allelix Biopharmaceuticals, Inc. Benzyl-substituted compounds having dopamine receptor affinity
US5602121A (en) * 1994-12-12 1997-02-11 Allelix Biopharmaceuticals, Inc. Alkyl-substituted compounds having dopamine receptor affinity
SE9500998D0 (sv) 1995-03-19 1995-03-19 Haakan Wilhelm Wikstroem New sulfone ester analogues of iso-clozapine and related structures: atypical neuroleptics
GB9617305D0 (en) * 1996-08-17 1996-09-25 Glaxo Wellcome Spa Heterocyclic compounds
KR100672186B1 (ko) 1998-03-31 2007-01-19 아카디아 파마슈티칼스 인코포레이티드 무스카린 수용체에 대해 활성을 갖는 화합물
GB9924962D0 (en) 1999-10-21 1999-12-22 Mrc Collaborative Centre Allosteric sites on muscarinic receptors
TWI310035B (en) * 2000-04-28 2009-05-21 Acadia Pharm Inc Muscarinic agonists
US6630462B2 (en) * 2000-11-17 2003-10-07 Adolor Corporation Delta agonist analgesics
US6890919B2 (en) 2001-06-26 2005-05-10 Shitij Kapur Atypical antipsychotic agents having low affinity for the D2 receptor
US7355042B2 (en) 2001-10-16 2008-04-08 Hypnion, Inc. Treatment of CNS disorders using CNS target modulators
DE10206941A1 (de) 2002-02-19 2003-09-25 Goetz Nowak Neue Arzneimittel
EP1492794B1 (en) * 2002-03-28 2007-12-12 Eli Lilly And Company Piperazine substituted aryl benzodiazepines and their use as dopamine receptor antagonists for the treatment of psychotic disorders
KR20050048633A (ko) 2002-09-18 2005-05-24 에프엠씨 코포레이션 살충성 트라이사이클릭 유도체
WO2004056182A1 (en) 2002-12-20 2004-07-08 Basf Aktiengesellschaft Pesticidal dibenzo(hetero)azepine derivatives
ATE407117T1 (de) 2003-01-16 2008-09-15 Acadia Pharm Inc Selektive serotonin 2a/2c inverse rezeptoragonisten als therapeutika für neurodegenerative erkrankungen
US20050250767A1 (en) * 2003-01-23 2005-11-10 Weiner David M Use of N-desmethylclozapine to treat human neuropsychiatric disease
WO2004064753A2 (en) 2003-01-23 2004-08-05 Acadia Pharmaceuticals Inc Use of n-desmethylclozapine to treat human neuropsychiatric disease
US20050085463A1 (en) * 2003-01-23 2005-04-21 Weiner David M. Use of N-desmethylclozapine to treat human neuropsychiatric disease
US20070275957A1 (en) * 2003-01-23 2007-11-29 Weiner David M Use of n-desmethylclozapine to treat human neuropsychiatric disease
WO2004073639A2 (en) 2003-02-19 2004-09-02 Merck & Co. Inc. Treatment of psychosis with a muscarinic m1 receptor ectopic activator
DE10310196A1 (de) 2003-03-06 2004-09-23 Rina-Netzwerk Rna Technologien Gmbh Verwendung eines trizyklischen Antidepressivums zur Förderung der Endozytose
BRPI0412127A (pt) 2003-07-02 2006-08-15 Astrazeneca Ab método de tratar pelo menos um sintoma ou condição, uso de um composto, composição farmacêutica, e uso da mesma
BRPI0417749A (pt) 2003-12-22 2007-04-10 Acadia Pharm Inc composto, método de sintese de composto, bibliotecas combinatórias, composições farmacêuticas e métodos de tratamento de disfunções neuropsiquiátricas
EP1726952A4 (en) 2004-02-20 2008-06-18 Dainippon Sumitomo Pharma Co METHOD FOR IN VIVO SCREENING OF A THERAPEUTIC FOR A MEMORY / LEARNING FUNCTION THROUGH SCHIZOPHRENIA
BRPI0509524A (pt) * 2004-04-01 2007-09-18 Acadia Pharm Inc formas cristalinas de n-desmetilclozapina
CA2576153A1 (en) 2004-08-05 2006-02-16 Acadia Pharmaceuticals Inc. Use of n-desmethylclozapine to treat human neuropsychiatric disease
EP1804804B1 (en) 2004-09-21 2012-01-25 Hypnion, Inc. 3-[4-(DIBENZO[b,f][1,4]OXAZEPIN-11-YL)-PIPERAZIN-1-YL]-2,2-DIMETHYL PROPANOIC ACID FOR USE IN THE TREATMENT OF SLEEP DISORDERS
US20060063754A1 (en) * 2004-09-21 2006-03-23 Edgar Dale M Methods of treating a sleep disorder
US7563785B2 (en) 2004-10-29 2009-07-21 Hypnion, Inc. Quetiapine analogs and methods of use thereof
WO2006081327A2 (en) 2005-01-25 2006-08-03 University Of Vermont And State Agricultural College Small molecules that reduce fungal growth
AU2006214517A1 (en) 2005-02-14 2006-08-24 Combinatorx, Incorporated Compounds and uses thereof
US20060252744A1 (en) * 2005-04-04 2006-11-09 Burstein Ethan S Use of N-desmethylclozapine and related compounds as dopamine stabilizing agents
WO2007053618A1 (en) * 2005-10-31 2007-05-10 Acadia Pharmaceuticals Inc. Prodrugs of muscarinic agonists and methods of treatment of neuropsychiatric disorders
JP2009516708A (ja) 2005-11-18 2009-04-23 アストラゼネカ・アクチエボラーグ 液体製剤
EP1951257A4 (en) 2005-11-18 2008-11-05 Astrazeneca Ab CRYSTALLINE FORMS
WO2007062338A2 (en) 2005-11-18 2007-05-31 Astrazeneca Ab Solid formulations
EP1951694A4 (en) 2005-11-18 2010-09-22 Astrazeneca Ab FORMS OF SALTS
WO2008002602A1 (en) 2006-06-27 2008-01-03 Acadia Pharmaceuticals Inc. Use of n-desmethylclozapine to treat psychosis
WO2008066620A2 (en) 2006-10-20 2008-06-05 Concert Pharmaceuticals Inc. Dibenzothiazepine derivatives

Also Published As

Publication number Publication date
EP1696931B1 (en) 2009-03-25
US20050192268A1 (en) 2005-09-01
PT1696931E (pt) 2009-06-12
DK1696931T3 (da) 2009-06-29
US7550454B2 (en) 2009-06-23
IL176447A0 (en) 2006-10-05
NO20063371L (no) 2006-09-22
JP2007534656A (ja) 2007-11-29
EP2088147A1 (en) 2009-08-12
US7622461B2 (en) 2009-11-24
MXPA06007244A (es) 2006-08-18
US7517871B2 (en) 2009-04-14
KR20060128943A (ko) 2006-12-14
US7491715B2 (en) 2009-02-17
US20100129473A1 (en) 2010-05-27
CY1109171T1 (el) 2014-07-02
WO2005063254A2 (en) 2005-07-14
PL1696931T3 (pl) 2009-10-30
AU2004308955A1 (en) 2005-07-14
BRPI0417749A (pt) 2007-04-10
CA2550735A1 (en) 2005-07-14
AU2004308955B2 (en) 2011-08-04
KR101157881B1 (ko) 2012-07-06
NZ547911A (en) 2010-06-25
ES2324713T3 (es) 2009-08-13
WO2005063254A3 (en) 2005-09-15
US20070197502A1 (en) 2007-08-23
SI1696931T1 (sl) 2009-08-31
US20060199798A1 (en) 2006-09-07
US20060194784A1 (en) 2006-08-31
CN101962369A (zh) 2011-02-02
HK1095092A1 (en) 2007-04-27
DE602004020263D1 (de) 2009-05-07
SG133606A1 (en) 2007-07-30
EP1696931A2 (en) 2006-09-06

Similar Documents

Publication Publication Date Title
DE602004020263D1 (de) Amino-substituierte diaryläa,dücyclohepten- analoga als muscarinische agonisten und verfahren zur behandlung von neuropsychiatrischen erkrankungen
DE60216830D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen
ATE435012T1 (de) Verfahren zur behandlung von parkinson-krankheit
DE60134453D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von ZNS und anderen Krankheiten
EP1507765A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM AND PERIPHERAL NERVOUS SYSTEM DISORDERS AND RELATED COMPOUNDS
EA200401365A1 (ru) Способы лечения илеуса
DE69535498D1 (de) Verfahren zur behandlung vaskulärer kopfschmerzen
DE60144123D1 (de) Verfahren zur Behandlung von Arzneimittelinduzierter peripherer Neuropathie und verwandten Krankheitsformen
DE602004002394D1 (de) (3-ä3-'(2,4-BIS-TRIFLUORMETHYL-BENZYL)-(5-ETHYL-PYRIMIDIN-2-YL)-AMINOÜ-PROPOXYü-PHENYL)-ESSIGSÄURE UND VERWANDTE VERBINDUNGEN ALS MODULATOREN VON PPARS UND VERFAHREN ZUR BEHANDLUNG VON STOFFWECHSELSTÖRUNGEN
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
ATE521357T1 (de) Verfahren zur behandlung von hepatitis
AU2003238007A8 (en) Methods of treating alzheimer's disease using aryl alkanoic acid amides
DE60112766D1 (de) Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen
ATE384699T1 (de) 2,6-chinolinyl- und 2,6-naphthylderivate und deren verwendungen zur behandlung von vla-4 bezogenen krankheiten
ATE331527T1 (de) Verfahren zur behandlung von brustdrüsenerkrankungen
ATE357438T1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
DE60021908D1 (de) Hydroxyeicosatetraenoatsalze, zusammensetzungen und verfahren zur verwendung zur behandlung des trockenen auges
ATE435026T1 (de) Verfahren zur prävention und behandlung von diabetes mit neurturin
ATE225171T1 (de) Aminosäurederivate zur behandlung von schlaganfall
HUP0103712A2 (hu) Paroxetin sók, eljárás az előállításukra és gyógyászati alkalmazásuk
ATE513471T1 (de) Verfahren und zusammensetzungen zur behandlung von erkrankungen
ATE239470T1 (de) Melatonin-derivate zur verwendung in der behandlung von desynchronisierungs-erkankungen
DE502004004324D1 (de) Maschine zur Behandlung eines Gleises
DE50010234D1 (de) Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz
DE10390484D2 (de) Verfahren und Vorrichtung zur Aufbereitung von Abwässern

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1696931

Country of ref document: EP